Skip to main content Skip to section navigation Skip to footer
ProMIS Neurosciences, Inc.
  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Business Advisory Board
  • Our Science
  • Product Pipeline
    • Overview
    • Alzheimer’s Disease
    • ALS
    • Parkinson’s Disease
    • Posters & Publications
  • News & Media
    • Press Releases
    • Corporate Presentations
    • Events
    • In The News
    • Videos
    • Commentary
    • Podcasts
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEDAR
    • SEC Filings
    • Governance
  • Careers
  • Contact

In The News

News & Media

News & Media

  • Press Releases
  • Corporate Presentations
  • Events
  • In The News
  • Videos
  • Commentary
  • Podcasts
May 28, 2019

Guest Commentary: Targeting α-synuclein and the pathogenesis of Parkinson’s disease

Feb 28, 2019

Attacking the Right Therapeutic Target in Alzheimer’s Disease

Feb 1, 2019

Could Roche’s Alzheimer’s drug failure be Promis Neurosciences gain?

Dec 18, 2018

ProMIS tackles Parkinson's and Alzheimer’s diseases

Dec 18, 2018

ProMIS Neurosciences (TSX:PMN): Targeting the root cause of Alzheimer’s and other neurodegenerative diseases

Sep 12, 2018

Stockhouse - The Key to Unlocking Alzheimers Treatment?

Sep 12, 2018

Global Business Report – Interview with Eugene Williams Executive Chairman, ProMIS

Aug 27, 2018

ProMIS’ PMN310 Shows Improved Safety Profile, Specificity Compared to Similar Alzheimer’s Candidates

Jul 9, 2018

Why Hope Endures For An Alzheimer's Treatment — And Biogen Could Be First

Jun 21, 2018

ProMIS Trial Offers Hope For Alzheimer's Patients

rss_feed RSS
  • arrow_back
  • 1
  • 2
  • 3
  • 4
  • 5
  • arrow_forward
Facebook Linkedin Spotify Twitter
©2022 ProMIS Neurosciences, Inc. All Rights Reserved.
Disclaimer Sitemap Cookie Policy Privacy Policy